Johnson & Johnson JNJ

Johnson & Johnson’s first-quarter 2026 filing lands with the quiet thud of a stethoscope dropped on a linoleum floor: sales climbed to $24.06 billion, net income came in at $5.24 billion, and diluted EPS printed $2.14, all for the quarter ended 29 March 2026. Cash and equivalents sat at $21.69 billion, while operations coughed up $2.51 billion in net cash, giving the balance sheet a sturdy look even before the dividend hike (source: JNJ 10-Q (2026-04-22), https://www.sec.gov/Archives/edgar/data/200406/000020040626000087/jnj-20260329.htm).

What Johnson & Johnson actually does is sprawling: from mental-health tech and urban substance-abuse clinics to rural care delivery systems, the company markets itself as the Swiss-army-knife of global health. Its rare-disease pipeline includes a targeted therapy in clinical trials, the sort of asset that can make a blockbuster look like a single-use bandage. The problem is the optics: when a business that spans Band-Aids and billion-dollar acquisitions reports $1.2 billion in amortisation costs, the narrative starts to feel less like a diversified champion and more like a theme park where every ride has a maintenance fee (source: Johnson & Johnson: Changing health for humanity, https://www.jnj.com).

The filings themselves tell a tighter story. Total assets weighed in at $200.89 billion, liabilities at $119.71 billion, and shareholders’ equity at $81.19 billion. Capital expenditure for the quarter ran to $1.05 billion, while inventory rose by $431 million-a build that might reflect supply-chain resilience or the corporate version of buying three jars of pickles just in case. Weighted average diluted shares came to 2.45 billion, so the $2.14 EPS is the arithmetic result of a lot of moving parts (source: JNJ 10-Q (2026-04-22), https://www.sec.gov/Archives/edgar/data/200406/000020040626000087/jnj-20260329.htm).

If you’re hunting for a chart, the SEC filings won’t give you candles, but the company’s own investor pages and EDGAR submissions JSON offer the raw backbone: revenue breakdowns, segment notes, and dividend history. The question is whether the market sees a durable franchise or a conglomerate struggling to keep the noise under control. One dividend increase and a rising inventory line do not a thesis make; the next proving ground is execution against that sprawling portfolio (source: JNJ SEC EDGAR submissions JSON, https://data.sec.gov/submissions/CIK0000200406.json).

What’s still missing is segment-level granularity and forward guidance beyond the dividend math. The 10-Q acknowledges U.S. rebates and discounts adjustments at 4.7% of revenue-material enough to shape margins but thin on detail about which franchises are bearing the brunt. The 11-K filings drop more colour on inventories and R&D, yet the R&D line at $109 million for the full-year 2025 feels light for a group of this scale. Analysts will want to see whether the inventory build is strategic stockpiling or the corporate equivalent of panic-buying at Costco (source: JNJ 10-K (2026-06-25), https://www.sec.gov/Archives/edgar/data/200406/000020040626000137/jnj-20260623.htm).